Hormonal
Semaglutide 2.4 mg administered subcutaneously once-weekly produces significant body weight reduction (mean 12.2 kg or 11.8%) and improves cardiometabolic parameters in adults with obesity, with real-world evidence confirming efficacy similar to randomized controlled trials.
Semaglutide 2.4mg once weekly is a highly effective treatment for obesity, producing an average 12kg weight loss when combined with lifestyle changes. Real-world data confirms it works as well as in clinical trials. Be aware of common side effects like nausea, which often subside, and discuss cost-effectiveness with your provider as it varies by region and insurance.
According to data from the STEP clinical trials programme, administration of semaglutide 2.4 mg, compared to placebo, in overweight or obese individuals without baseline T2DM results in a significant reduction in body weight by 11.8%, equal to a mean reduction of 12.2 kg in absolute body weight... Real-world evidence suggests that, besides the significant improvement in body weight, individuals assigned to semaglutide, regardless of concomitant diabetes mellitus, experienced a significant improvement in other cardio-metabolic parameters of interest
Why this rating
Supported by large RCTs (STEP) and corroborated by multiple real-world observational studies.
Source
Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care
Dimitrios Patoulias et al. · Pragmatic and Observational Research · 2024
DOI 10.2147/por.s471476
More from this paper
- Tirzepatide, a dual GLP-1/GIP receptor agonist, produces significantly greater body weight reduction (up to 20.9% at 15mg) compared to semaglutide and other GLP-1 agonists in patients with obesity, with real-world studies confirming superior efficacy.Good
- Liraglutide 3.0 mg administered subcutaneously once daily produces significant but numerically lower weight loss compared to semaglutide and is less cost-effective, though it remains a safe and efficacious option for obesity management.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →